Study to Evaluate the Bioavailability of Tislelizumab Via Subcutaneous Injection in First-Line Treatment of Participants With Advanced or Metastatic Non-Small Cell Lung Cancer
Clinical trial NCT06091943 · COMPLETED
Trial details
- NCT number
- NCT06091943
- Sponsor
- BeiGene
- Status
- COMPLETED
- Phase
- Phase 1
- Study type
- INTERVENTIONAL
- Start date
- 2023-11-16
- Primary completion
- 2025-07-31
- Enrollment
- 62
Track trials programmatically
Sponsors, conditions and status changes through the Atlas API.